Loading…
Haemonetics Corporation is projected to rise to $103.43 by 2027, a +36% move from its current price of $76.19. HAE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $74.78 | $76.27 | $77.78 | +0.10% |
| Jul 14 | $74.25 | $76.35 | $78.50 | +0.21% |
| Jul 15 | $73.87 | $76.43 | $79.08 | +0.31% |
| Jul 16 | $73.55 | $76.51 | $79.58 | +0.41% |
| Jul 17 | $73.29 | $76.58 | $80.03 | +0.52% |
| Jul 18 | $73.06 | $76.66 | $80.45 | +0.62% |
| Jul 19 | $72.85 | $76.74 | $80.84 | +0.73% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $72.85 | $76.74 | $80.84 | +0.73% |
| Week 2 | $71.81 | $77.30 | $83.21 | +1.46% |
| Week 3 | $71.14 | $77.86 | $85.21 | +2.19% |
| Week 4 | $70.67 | $78.42 | $87.03 | +2.93% |
| Week 5 | $70.31 | $78.99 | $88.75 | +3.68% |
| Week 6 | $70.04 | $79.57 | $90.39 | +4.43% |
| Week 7 | $69.83 | $80.14 | $91.98 | +5.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Haemonetics Corporation is a medical technology company that provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments and offers automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools.
It also offers treatment across electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company provides hospital products comprising the TEG 6s system, the smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; vascular closure products such as VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions.
It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Haemonetics Corporation trades as a healthcare technology company focused on hospital-based solutions. The current price is $72.73 per share, with a market cap of $3.31B and a market-rank listing of 1671. The stock sits within the healthcare sector and provides a broad suite of plasma collection, donor management, and transfusion-related technologies alongside clinical workflow and information systems.
The latest price context shows a current price of $72.73 with a market capitalization of $3.31B and a rank of 1671. The 2026 outlook is neutral at an average of $72.73, with a min of $52.24 and a max of $108.89, while the broader multi-year view turns bullish from 2027 onward, showing steady upside through 2050. The forecast implies strong upside potential in the long horizon, with 2040 averaging $393.66 and 2050 averaging $793.13, accompanied by substantial ROI figures across the horizon.
A major floor 31.4% below — a decisive break under it would weaken the trend.
The nearest floor, 13.5% below — buyers have tended to step in here.
The nearest ceiling, 4.8% above — a clean break opens room to run.
A major ceiling 15.4% above — clearing it would confirm fresh momentum.
Key HAE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HAE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $74.98 | Buy | $75.23 | Buy |
| MA 10 | $75.22 | Buy | $75.04 | Buy |
| MA 20 | $75.22 | Buy | $74.07 | Buy |
| MA 50 | $67.51 | Buy | $69.94 | Buy |
| MA 100 | $63.78 | Buy | $67.21 | Buy |
| MA 200 | $65.37 | Buy | $66.35 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.67 | Neutral |
| Stoch RSI (14) | 53.77 | Neutral |
| CCI (20) | 44.01 | Neutral |
| Williams %R (14) | -28.09 | Info |
| MACD (12,26,9) | -0.51 | Sell |
| ROC (12) | 4.69 | Buy |
| Bollinger %B (20,2) | 0.63 | Neutral |
| Stochastic %K (14) | 71.91 | Neutral |
| TRIX (15) | 0.49 | Buy |
| Awesome (5,34) | 2.23 | Buy |
| Ultimate (7,14,28) | 62.27 | Neutral |
| Momentum (10) | -1.43 | Sell |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 74.87 | Buy |
| ADX (14) | 23.34 | Buy |
| ATR (14) | 1.15 | Info |
The 30-day technical picture is bullish in sentiment. The RSI(14) sits at 60, suggesting room for upward movement without overbought risk. The short-term moving averages show the SMA50 at $63.09 and the SMA200 at $63.70, indicating a near-term upward tilt.
The stock’s latest 30-day range spans from $61.97 to $85.36, with defined support at $52.24 and resistance at $79.84, offering a framework for near-term price activity.
The current setup aligns with a constructive short-term bias, supported by the bullish sentiment in the near-term price pattern and the proximity of the price to the resistance area around $79.84. Investors should watch for a breakout above that level or a pullback toward the support near $52.24 for potential new directional cues.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $52.24 | $76.19 | $111.15 | 0% | Neutral | |
| $84.48 | $103.43 | $132.57 | +36% | Bullish | |
| $92.31 | $115.24 | $151.86 | +51% | Bullish | |
| $106.49 | $135.10 | $181.97 | +77% | Bullish | |
| $109.18 | $140.48 | $192.75 | +84% | Bullish | |
| $118.19 | $154.03 | $214.81 | +102% | Bullish | |
| $134.27 | $177.05 | $250.57 | +132% | Bullish | |
| $152.91 | $203.87 | $292.38 | +168% | Bullish | |
| $182.60 | $246.00 | $357.18 | +223% | Bullish | |
| $193.43 | $263.19 | $386.54 | +245% | Bullish | |
| $272.95 | $388.23 | $598.48 | +410% | Bullish | |
| $537.38 | $823.03 | $1,363.08 | +980% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $52.24 | $76.19 | $91.73 | +0.00% |
| August 2026 | $69.59 | $81.52 | $97.61 | +7.00% |
| September 2026 | $71.10 | $83.71 | $101.05 | +2.68% |
| October 2026 | $71.47 | $84.51 | $102.71 | +0.95% |
| November 2026 | $73.68 | $87.43 | $106.89 | +3.47% |
| December 2026 | $75.95 | $90.44 | $111.15 | +3.44% |
Click any year to see its month-by-month HAE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect HAE to range from $52.24 to $111.15 through 2026. The $76.19 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The HAE price prediction for 2027 points to an average of $103.43 (low $84.48, high $132.57) — a potential gain of +36% on today's $76.19. Momentum favours further upside here.
In 2028, HAE is projected to trade between $92.31 and $151.86, averaging $115.24 — a potential gain of +51% from today's $76.19. That is up +11% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Haemonetics Corporation's 2029 outlook centres on $135.10, within a $106.49 to $181.97 range. That is up +17% on the projected 2028 average. That marks a +77% change versus current levels. Momentum favours further upside here.
By 2030, HAE could reach as high as $192.75, with a base case around $140.48 and support toward $109.18 — roughly +84% from $76.19. Buyers look set to stay in control over this stretch.
Expect HAE to range from $118.19 to $214.81 through 2031. The $154.03 average target implies a +102% move from current prices. That is up +10% on the projected 2030 average. Momentum favours further upside here.
The HAE price prediction for 2032 points to an average of $177.05 (low $134.27, high $250.57) — a potential gain of +132% on today's $76.19. Buyers look set to stay in control over this stretch.
In 2033, HAE is projected to trade between $152.91 and $292.38, averaging $203.87 — a potential gain of +168% from today's $76.19. That is up +15% on the projected 2032 average. Momentum favours further upside here.
Haemonetics Corporation's 2034 outlook centres on $246.00, within a $182.60 to $357.18 range. That is up +21% on the projected 2033 average. That marks a +223% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, HAE could reach as high as $386.54, with a base case around $263.19 and support toward $193.43 — roughly +245% from $76.19. Momentum favours further upside here.
Expect HAE to range from $272.95 to $598.48 through 2040. The $388.23 average target implies a +410% move from current prices. That is up +48% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The HAE price prediction for 2050 points to an average of $823.03 (low $537.38, high $1,363.08) — a potential gain of +980% on today's $76.19. Momentum favours further upside here.
Investing $1,000 in HAE today (≈ 13.125082 HAE) could be worth
$10,802.38
+$9,802.38 (+980%) by 2050 · US Dollar
Based on the average projected HAE price of $823.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HAEwould be worth at today's price.
$1,000 invested in HAE on Jul 10, 2025 (≈ 12.792632 HAE) would be worth
$974.67
-$25.33 (-2.5%) today · 0.97× · US Dollar
Based on a HAE entry price of $78.17 vs. today's $76.19.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $75.07 | $1,014.92 | +1.5% |
| 1 month ago | $78.8 | $966.88 | -3.3% |
| 3 months ago | $57.32 | $1,329.2 | +32.9% |
| 6 months ago | $82.92 | $918.84 | -8.1% |
| 1 year ago | $78.17 | $974.67 | -2.5% |
| All time (5.0y) ago | $61.88 | $1,231.25 | +23.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HAE forecast.
Our base-case forecast reaches $150.00 around 2031.
Implied market cap at $150.00: $6.82B
The multi-year forecast shows a sustained uptrend with meaningful upside through 2030 and beyond. For 2030 the avg price is $135.00 with a min of $101.88 and a max of $192.21, representing an 85.6% anticipated ROI and a bullish sentiment. The trajectory continues to strengthen in 2031 ($150.06 avg, max $217.79, min $111.43, ROI 106.3) and beyond, with 2032 at $171.61 avg and a max of $253.39 (ROI 135.9) and 2033 at $200.64 avg with a max of $300.95 (ROI 175.9).
Looking further, 2034 shows $245.30 avg and $373.28 max (ROI 237.3), 2035 $254.68 avg and $392.80 max (ROI 250.2). The forecast projects substantial long-horizon strength, with 2040 averaging $393.66 and a max of $642.46 (ROI 441.3), and 2050 averaging $793.13 with a max of $1,406.37 (ROI 990.5), all described within a bullish sentiment framework. While these are explicit forecast figures, they remain estimates and are not guarantees; variability and risk are inherent in long-range projections.
Tap a question to reveal the answer.
In 2030 the avg price is $135.00 with a min of $101.88 and a max of $192.21; ROI 85.6%; sentiment bullish.
The forecast shows bullish sentiment from 2027 onward with rising averages (2027 avg $100.10; 2028 $113.88; 2029 $130.77; 2030 $135.00) while 2026 is neutral (avg $72.73). These are estimates, not guarantees.
Yes. The forecast max reaches $300.95 in 2033 and continues higher, with 2034 max $373.28 and 2035 max $392.80, plus up to $642.46 in 2040 and $1,406.37 in 2050.
The 30-day range is $61.97 to $85.36. RSI(14) is 60. The SMA50 is $63.09 and SMA200 is $63.70. Support is $52.24 and resistance is $79.84.
Current price is $72.73 and market cap is $3.31B.
Haemonetics Corporation Community Discussion
0Share your Haemonetics Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.